{rfName}
Cl

Indexed in

License and Use

Icono OpenAccess

Citations

37

Altmetrics

Analysis of institutional authors

Arribas, Maria VelascoAuthor

Share

March 14, 2025
Publications
>
Review
Sí

Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus

Publicated to: Journal of Clinical Medicine. 13 (21): 6509- - 2024-11-01 13(21), DOI: 10.3390/jcm13216509

Authors:

Gorgojo-Martínez, JJ; Górriz, JL; Cebrián-Cuenca, A; Conde, AC; Arribas, MV
[+]

Affiliations

Hlth Ctr Casco Antiguo Cartagena, Biomed Res Inst Murcia IMIB, Primary Care Res Grp, Cartagena 30201, Murcia, Spain - Author
Hosp Univ Fdn Alcorcon, Dept Endocrinol & Nutr, Madrid 28922, Spain - Author
Hosp Univ Fdn Alcorcon, Dept Infect Dis, Res Dept, Madrid 28922, Spain - Author
Univ Hosp La Paz IdiPAZ, Biomed Res Ctr Cardiovasc Dis, Dept Cardiol, Stroke Ctr,CIBERCV,ISCIII, Madrid 28046, Spain - Author
Univ Valencia, Valencia Clin Univ Hosp, Dept Nephrol, Inst Invest Sanitaria INCL, Valencia 46010, Spain - Author
See more

Abstract

Background: SGLT-2 inhibitors (SGLT-2is) are considered to be a first-line treatment for common conditions like type 2 diabetes, chronic kidney disease, and heart failure due to their proven ability to reduce cardiovascular and renal morbidity and mortality. Despite these benefits, SGLT-2is are associated with certain adverse effects (AEs), particularly genitourinary (GU) events, which can lead to treatment discontinuation in some patients. Preventing these AEs is essential for maintaining the cardiorenal benefits of SGLT-2is. Methods: A multidisciplinary panel of experts from various medical specialties reviewed the best available evidence on GU AEs associated with SGLT-2i therapy. The panel focused on the prevention and management of genital mycotic infections, urinary tract infections, and lower urinary tract symptoms in both the general population and high-risk groups, such as renal and cardiac transplant recipients. Results: The panel found that permanent discontinuation of SGLT-2is results in a rapid loss of cardiorenal benefits. Preventive strategies, including identifying high-risk patients before initiating therapy, are critical for minimizing GU AEs. Clinical trials show that most GU infections linked to SGLT-2i therapy are mild to moderate in severity and typically respond to standard antimicrobial treatment, without the need for discontinuation. Conclusions: Routine discontinuation of SGLT-2is due to GU AEs is not recommended. Therapy should be resumed as soon as possible, unless severe or persistent conditions contraindicate their use, in order to preserve the significant benefits of SGLT-2is in reducing cardiovascular and renal events
[+]

Keywords

Cotransporter 2 inhibitorsDiseases societyDouble-blindEmpaglifloziGenital fungal-infectionsGenital mycotic infectionGenitourinary infectionPractice guidelineSafetySglt-2 inhibitorsSodiumUrinary tract infectioUrinary tract infectionUrinary-tract-infectionsWomen

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal of Clinical Medicine due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 65/332, thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine, General & Internal.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-04:

  • WoS: 19
  • Scopus: 1
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 57.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 57 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 116.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 206 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Velasco Arribas, María).

[+]